NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free HROW Stock Alerts $16.16 +0.23 (+1.44%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$15.78▼$16.3650-Day Range$10.00▼$16.2452-Week Range$7.60▼$24.19Volume512,799 shsAverage Volume472,385 shsMarket Capitalization$571.77 millionP/E RatioN/ADividend YieldN/APrice Target$29.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Harrow alerts: Email Address Harrow MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside84.4% Upside$29.80 Price TargetShort InterestBearish15.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 27 Articles This WeekInsider TradingAcquiring Shares$1.86 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.39) to $0.69 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.88 out of 5 starsMedical Sector415th out of 929 stocksPharmaceutical Preparations Industry195th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingHarrow has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarrow has only been the subject of 2 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.54% of the outstanding shares of Harrow have been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Harrow has recently decreased by 7.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 2.4 News and Social Media Coverage News SentimentHarrow has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Harrow this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows4 people have added Harrow to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,864,011.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.60% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow are expected to grow in the coming year, from ($0.39) to $0.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -17.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -17.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 8.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About Harrow Stock (NASDAQ:HROW)Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More HROW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HROW Stock News HeadlinesApril 26, 2024 | insidertrades.comHarrow Health, Inc. (NASDAQ:HROW) Major Shareholder Purchases $199,400.00 in StockApril 25, 2024 | insidertrades.comOpaleye Management Inc. Purchases 11,715 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockApril 21, 2024 | insidertrades.comOpaleye Management Inc. Acquires 29,400 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockMay 16 at 3:02 AM | americanbankingnews.comHarrow, Inc. (NASDAQ:HROW) Expected to Earn Q4 2024 Earnings of $0.17 Per ShareMay 15 at 10:45 AM | insidermonkey.comHarrow Health, Inc. (NASDAQ:HROW) Q1 2024 Earnings Call TranscriptMay 15 at 7:00 AM | businesswire.comHarrow to Present at Two Investor Conferences in MayMay 15 at 5:45 AM | finance.yahoo.comHarrow Inc (HROW) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic AdvancesMay 15 at 12:44 AM | finance.yahoo.comHarrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo FinanceMay 15 at 12:44 AM | markets.businessinsider.comHarrow Health’s Promising Growth Trajectory and Strong Financial Outlook Reinforce Buy RatingMay 14 at 10:48 AM | seekingalpha.comHarrow, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 13 at 9:30 PM | investorplace.comHROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q1 2024May 13 at 4:34 PM | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Harrow Health (HROW)May 13 at 4:01 PM | businesswire.comHarrow Announces First Quarter 2024 Financial ResultsMay 13 at 7:00 AM | businesswire.comHarrow Names Greg DiPasquale as Senior Vice President, Head of CommercialMay 11, 2024 | americanbankingnews.comHarrow (HROW) Scheduled to Post Earnings on MondayMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)May 2, 2024 | seekingalpha.comHarrow: Merits A Buy On Sales PotentialMay 2, 2024 | seekingalpha.comHarrow: The Bull Thesis Is On Track, But Short-Term Challenges LoomApril 25, 2024 | businesswire.comHarrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024April 20, 2024 | finance.yahoo.comHarrow, Inc. (HROW)April 3, 2024 | bizjournals.comMelt Pharmaceuticals raises $24 million for drug developmentApril 2, 2024 | finance.yahoo.comMelt Pharmaceuticals Closes $24 Million Series B Preferred Stock FinancingMarch 21, 2024 | finance.yahoo.comHarrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comWhy Is Harrow (HROW) Stock Up 5% Today?March 20, 2024 | seekingalpha.comHarrow, Inc. 2023 Q4 - Results - Earnings Call PresentationSee More Headlines Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today5/16/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Target$29.80 High Stock Price Target$34.40 Low Stock Price Target$26.00 Potential Upside/Downside+84.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,410,000.00 Net Margins-22.59% Pretax Margin-18.21% Return on Equity-40.58% Return on Assets-8.28% Debt Debt-to-Equity Ratio2.60 Current Ratio2.83 Quick Ratio2.61 Sales & Book Value Annual Sales$138.68 million Price / Sales4.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book8.04Miscellaneous Outstanding Shares35,382,000Free Float30,570,000Market Cap$571.77 million OptionableOptionable Beta0.58 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsOlema PharmaceuticalsNASDAQ:OLMAAvid BioservicesNASDAQ:CDMOCOMPASS PathwaysNASDAQ:CMPSSIGA TechnologiesNASDAQ:SIGAAltimmuneNASDAQ:ALTView All CompetitorsInsiders & InstitutionsKennedy Capital Management LLCSold 644 shares on 5/16/2024Ownership: 0.336%California State Teachers Retirement SystemSold 3,278 shares on 5/16/2024Ownership: 0.084%Bayesian Capital Management LPBought 14,002 shares on 5/16/2024Ownership: 0.040%Price T Rowe Associates Inc. MDBought 1,033 shares on 5/15/2024Ownership: 0.047%Vanguard Group Inc.Bought 21,253 shares on 5/10/2024Ownership: 5.172%View All Insider TransactionsView All Institutional Transactions HROW Stock Analysis - Frequently Asked Questions Should I buy or sell Harrow stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harrow in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks. What is Harrow's stock price target for 2024? 2 Wall Street analysts have issued 12-month price objectives for Harrow's stock. Their HROW share price targets range from $26.00 to $34.40. On average, they anticipate the company's stock price to reach $29.80 in the next twelve months. This suggests a possible upside of 84.4% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts. How have HROW shares performed in 2024? Harrow's stock was trading at $11.20 at the beginning of 2024. Since then, HROW stock has increased by 44.3% and is now trading at $16.16. View the best growth stocks for 2024 here. When is Harrow's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our HROW earnings forecast. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) issued its earnings results on Tuesday, March, 19th. The company reported ($0.27) earnings per share for the quarter. The company earned $36.36 million during the quarter, compared to the consensus estimate of $37.65 million. Harrow had a negative net margin of 22.59% and a negative trailing twelve-month return on equity of 40.58%. What ETF holds Harrow's stock? Jacob Forward ETF holds 10,594 shares of HROW stock, representing 3.75% of its portfolio. What guidance has Harrow issued on next quarter's earnings? Harrow updated its FY 2024 earnings guidance on Monday, May, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.0 million-, compared to the consensus revenue estimate of $184.8 million. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO). Who are Harrow's major shareholders? Harrow's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.17%), Wasatch Advisors LP (1.10%), Rice Hall James & Associates LLC (0.69%), Woodmont Investment Counsel LLC (0.60%), Kennedy Capital Management LLC (0.34%) and Equitable Trust Co. (0.24%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HROW) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe #1 Investment of the Decade… Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityWhy Is Gold On a MASSIVE rally? Huge AlertsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
